The Cancer Letter

Inside information on cancer research and drug development

Robert Winn introduces “Inclusive Excellence” as his AACI presidential initiative

“If we’re going to be inclusive, then we need to be inclusive.”

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

As Robert A. Winn begins his two-year term as president of the Association of American Cancer Institutes, his presidential initiative of “Inclusive Excellence” aims to increase collaboration among cancer centers, their communities, and other cancer organizations in the United States and abroad.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Alexandria Carolan
Alexandria Carolan
Reporter
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Among cancer survivors, LGBTQ+ individuals report higher prevalence of chronic health conditions, disabilities, other limitations

Cancer survivors who identify as lesbian, gay, bisexual, transgender, queer, or anything other than straight and cisgender experience more chronic health conditions, disabilities, and other physical and cognitive limitations than non-LGBTQ+ cancer survivors; however, the prevalence of most conditions was highest among transgender or gender non-conforming individuals, according to a study published in Cancer Epidemiology, Biomarkers & Prevention.
Clinical Roundup

Oncology drugs approved post-2020 more likely to include postmarketing approaches to collecting data in underrepresented populations

Friends of Cancer Research characterized postmarketing requirements and commitments over the last decade. The perspective article, titled “An evaluation of novel oncology approvals with a PMR/C for assessing data in racial and ethnic populations underrepresented in premarket clinical trials,” provides insights into FDA’s expectations for representation of race and ethnicity in oncology clinical trials.
Byline
Alexandria Carolan
Alexandria Carolan
Reporter
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account